🧫
Reelin treatment rescue via ApoER2 in CD2AP mutant mice
active
experiment
Created: 2026-04-06T12:34:46
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-46050ab8-3e9b-4b6f-adc3-767078ec6113
🧫 Experiment Protocol
ValidationAlzheimer's diseaseCD2APmiceproposed
Therapeutic intervention using reelin glycoprotein to mitigate CD2AP loss-of-function effects through ApoER2 receptor signaling. This experiment tested whether reelin treatment could rescue cerebrovascular dysfunction in CD2AP mutant mice by activating compensatory pathways. The study measured resting cerebral blood flow improvements and protection against amyloid-beta toxicity, with particular focus on male mice showing enhanced therapeutic response.
PRIMARY OUTCOME
increased resting cerebral blood flow and protection against Aβ toxicity
EXPECTED OUTCOMES
1. The intervention targeting CD2AP shifts increased resting cerebral blood flow and protection against Aβ toxicity in the predicted direction relative to the matched control arm.
2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (increased resting cerebral blood flow and protection against Aβ toxicity) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
- The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
- Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for CD2AP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure increased resting cerebral blood flow and protection against Aβ toxicity together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Therapeutic intervention using reelin glycoprotein to mitigate CD2AP loss-of-function effects through ApoER2 receptor signaling. This experiment tested whether reelin treatment could rescue cerebrovascular dysfunction in CD2AP mutant mice by activating compens
LINKED HYPOTHESES
Source: PMID 39892386 ↗
🧫 Experiment Extras
PATHWAY
reelin-ApoER2 signaling, cerebrovascular function
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.